Payment overview · 2025
General Payments
$1,384.76
62 reported records · 19 companies
Healthcare provider profile · identity verified
Dan Tran, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · ROSEMEAD, CA · NPI 1487709747
Verified facts
What the public records show
CMS Open Payments records show Dan Tran, M.D. received $1,384.76 in general payments during 2025 across 62 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Entresto, Gemtesa, Jardiance, Kerendia, Linzess, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 393 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Jardiance by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $298.37 | 21.6% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.53 | 16.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.15 | 12.7% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.01 | 9.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.09 | 9.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.55 | 5.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.97 | 3.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.94 | 3.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.04 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.69 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.97 | 1.8% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $24.39 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.91 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.85 | 1.6% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.01 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.34 | 1.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.31 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.79 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.85 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,384.76 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $298.37 | 16 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $234.53 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $161.70 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.53 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.53 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.28 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.28 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $49.46 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.28 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $7.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 46 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 368 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 316 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 124 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
124 | 53 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
164 | 108 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
393 | 92 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
316 | 64 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
368 | 83 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
124 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
368 | 83 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
41 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1624 | 430 |
| Amlodipine Besylate | Amlodipine Besylate | 1623 | 425 |
| Losartan Potassium | Losartan Potassium | 1488 | 369 |
| Omeprazole | Omeprazole | 904 | 302 |
| Metoprolol Succinate | Metoprolol Succinate | 833 | 220 |
| Gabapentin | Gabapentin | 752 | 239 |
| Metformin Hcl | Metformin Hcl | 699 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 658 | 191 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 520 | 271 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 490 | 250 |
| Celecoxib | Celecoxib | 417 | 234 |
| Farxiga | Dapagliflozin Propanediol | 393 | 92 |
| Alendronate Sodium | Alendronate Sodium | 388 | 133 |
| Jardiance | Empagliflozin | 368 | 83 |
| Azelastine Hcl | Azelastine Hcl | 350 | 139 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 323 | 74 |
| Kerendia | Finerenone | 316 | 64 |
| Januvia | Sitagliptin Phosphate | 306 | 55 |
| Atenolol | Atenolol | 301 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 300 | 121 |
| Benazepril Hcl | Benazepril Hcl | 264 | 74 |
| Ropinirole Hcl | Ropinirole Hcl | 259 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 60 |
| Glimepiride | Glimepiride | 237 | 60 |
| Simvastatin | Simvastatin | 232 | 50 |
| Glipizide | Glipizide | 228 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 214 | 63 |
| Lisinopril | Lisinopril | 214 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 206 | 53 |
| Meclizine Hcl | Meclizine Hcl | 196 | 124 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 92 |
| Donepezil Hcl | Donepezil Hcl | 180 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 106 |
| Prolia | Denosumab | 164 | 108 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 159 | 70 |
| Azithromycin | Azithromycin | 151 | 124 |
| Furosemide | Furosemide | 148 | 73 |
| Montelukast Sodium | Montelukast Sodium | 146 | 44 |
| Meloxicam | Meloxicam | 141 | 96 |
| Raloxifene Hcl | Raloxifene Hcl | 137 | 37 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 134 | 112 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 38 |
| Carvedilol | Carvedilol | 124 | 31 |
| Linzess | Linaclotide | 124 | 53 |
| Trazodone Hcl | Trazodone Hcl | 119 | 62 |
| Allopurinol | Allopurinol | 117 | 46 |
| Ozempic | Semaglutide | 116 | 25 |
| Prednisone | Prednisone | 114 | 87 |
| Sildenafil Citrate | Sildenafil Citrate | 110 | 29 |
| Clonidine Hcl | Clonidine Hcl | 109 | 60 |
| Tramadol Hcl | Tramadol Hcl | 109 | 37 |
| Metformin Hcl Er | Metformin Hcl | 104 | 37 |
| Potassium Chloride | Potassium Chloride | 99 | 55 |
| Terazosin Hcl | Terazosin Hcl | 98 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 94 | 76 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 87 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 22 |
| Repatha Sureclick | Evolocumab | 86 | 16 |
| Ibuprofen | Ibuprofen | 85 | 64 |
| Vemlidy | Tenofovir Alafenamide | 83 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 25 |
| Finasteride | Finasteride | 76 | 21 |
| Myrbetriq | Mirabegron | 76 | 17 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 75 | 21 |
| Febuxostat | Febuxostat | 75 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 73 | 20 |
| Tradjenta | Linagliptin | 73 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 72 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 21 |
| Amoxicillin | Amoxicillin | 71 | 58 |
| Eliquis | Apixaban | 70 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 21 |
| Nifedipine Er | Nifedipine | 65 | 16 |
| Hydrocortisone | Hydrocortisone | 63 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 22 |
| Famotidine | Famotidine | 58 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 17 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 54 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | 11 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 53 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Procto-Med Hc | Hydrocortisone | 53 | 31 |
| Rybelsus | Semaglutide | 50 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 33 |
| Pregabalin | Pregabalin | 49 | 18 |
| Xarelto | Rivaroxaban | 49 | 14 |
| Ezetimibe | Ezetimibe | 48 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 47 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Vascepa | Icosapent Ethyl | 47 | 20 |
| Creon | Lipase/Protease/Amylase | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Cyclosporine | Cyclosporine | 45 | 28 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 19 |
| Methimazole | Methimazole | 44 | 11 |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 12 |
| Colchicine | Colchicine | 41 | 25 |
| Gemtesa | Vibegron | 41 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 13 |
| Propranolol Hcl | Propranolol Hcl | 40 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 39 | suppressed |
| Naproxen | Naproxen | 39 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | 13 |
| Megestrol Acetate | Megestrol Acetate | 37 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 13 |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Loperamide | Loperamide Hcl | 35 | 33 |
| Fluocinonide | Fluocinonide | 34 | 30 |
| Restasis | Cyclosporine | 34 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Dutasteride | Dutasteride | 32 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Desmopressin Acetate | Desmopressin Acetate | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Acarbose | Acarbose | 27 | suppressed |
| Estradiol | Estradiol | 27 | 16 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 23 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | 11 |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | 12 |
| Diflorasone Diacetate | Diflorasone Diacetate | 20 | suppressed |
| Entecavir | Entecavir | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Ondansetron Odt | Ondansetron | 18 | 16 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 16 | suppressed |
| Propylthiouracil | Propylthiouracil | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Benzonatate | Benzonatate | 14 | 11 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,384.76 · 62 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, CREON, ENTRESTO, EVENITY, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, XEN GLAUCOMA TREATMENT SYSTEM, ZAVZPRET, ZEPBOUND, ZTLido | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error